TScan Therapeutics (TCRX) Debt Ratio (2022 - 2025)

TScan Therapeutics (TCRX) has disclosed Debt Ratio for 4 consecutive years, with 0.14 as the latest value for Q4 2025.

  • On a quarterly basis, Debt Ratio rose 64.55% to 0.14 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.14, a 64.55% increase, with the full-year FY2025 number at 0.14, up 64.55% from a year prior.
  • Debt Ratio was 0.14 for Q4 2025 at TScan Therapeutics, up from 0.12 in the prior quarter.
  • In the past five years, Debt Ratio ranged from a high of 0.18 in Q3 2022 to a low of 0.08 in Q2 2024.
  • A 4-year average of 0.12 and a median of 0.11 in 2025 define the central range for Debt Ratio.
  • Peak YoY movement for Debt Ratio: plummeted 41.52% in 2023, then soared 64.55% in 2025.
  • TScan Therapeutics' Debt Ratio stood at 0.15 in 2022, then dropped by 24.95% to 0.11 in 2023, then decreased by 21.73% to 0.09 in 2024, then skyrocketed by 64.55% to 0.14 in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Debt Ratio are 0.14 (Q4 2025), 0.12 (Q3 2025), and 0.11 (Q2 2025).